PRC200-SS explained

PRC200-SS is an experimental drug of the triple reuptake inhibitor class that was investigated by the Mayo Clinic.[1] [2]

Preclinical toxicology studies of PRC200-SS in cynomolgus monkeys showed dose proportional kidney toxicity,[3] precluding any further drug development.

Notes and References

  1. Liang Y, Shaw AM, Boules M, Briody S, Robinson J, Oliveros A, Blazar E, Williams K, Zhang Y, Carlier PR, Richelson E . 6 . Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS) . The Journal of Pharmacology and Experimental Therapeutics . 327 . 2 . 573–83 . November 2008 . 18689611 . 10.1124/jpet.108.143610 . 12635418 .
  2. Web site: Triple Reuptake Inhibitors for the Treatment of Depression . Mayo Clinic Ventures .
  3. Guha M, Heier A, Price S, Bielenstein M, Caccese RG, Heathcote DI, Simpson TR, Stong DB, Bodes E . 6 . Assessment of biomarkers of drug-induced kidney injury in cynomolgus monkeys treated with a triple reuptake inhibitor . Toxicological Sciences . 120 . 2 . 269–83 . April 2011 . 21258088 . 10.1093/toxsci/kfr013 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "PRC200-SS".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.